Univ of Colorado Dept of Opthalmology
Welcome,         Profile    Billing    Logout  
 3 Trials 
4 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Preston, Mary
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
NCT04417530: Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Completed
2
22
US
AU-011, Suprachoroidal Microinjector, PDT Laser
Aura Biosciences
Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
04/24
04/24
Subramanian, Prem
NCT05002998: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study

Active, not recruiting
4
313
Europe, US
Teprotumumab, TEPEZZA, Placebo, Saline Solution
Amgen
Thyroid Eye Disease
04/26
04/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )

Active, not recruiting
3
154
Europe, Canada, US, RoW
Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo
Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/24
03/25

Download Options